Activation of human B lymphocytes through CD40 and interleukin 4 - PubMed (original) (raw)
Activation of human B lymphocytes through CD40 and interleukin 4
A Vallé et al. Eur J Immunol. 1989 Aug.
Abstract
We have produced and characterized a new CD40 monoclonal antibody, mAb 89, which in the presence of anti-IgM antibodies co-stimulates to induce B cell proliferation. mAb 89 activates resting B cells as shown by an increase in cell volume and an enhanced subsequent proliferation of B cells in response to anti-IgM antibody. However, mAb 89 does not prepare B cells to respond to the growth-promoting activity of interleukin (IL) 2 or IL 4. Unlike IL 2 and IL 4, mAb 89 only weakly stimulates the proliferation of anti-IgM pre-activated B cells. Thus, the activating properties of anti-CD40 are likely to explain its co-stimulatory effect on B cells. Interestingly, the anti-CD40 mAb 89 was found to act in synergy with IL 4, but not with IL 2, in co-stimulation and restimulation assays. In this respect, anti-CD40 does not induce a significant increase of B cell surface IL 4 receptors while IL 4, but not IL 2, induces a twofold increase of the CD40 antigen expression. Thus the synergistic interaction between IL 4 and anti-CD40 may be related to the IL 4-dependent increase of CD40 antigen expression.
Similar articles
- Helper effector function of human T cells stimulated by anti-CD3 mAb can be enhanced by co-stimulatory signals and is partially dependent on CD40-CD40 ligand interaction.
Kwekkeboom J, de Rijk D, Kasran A, Barcy S, de Groot C, de Boer M. Kwekkeboom J, et al. Eur J Immunol. 1994 Mar;24(3):508-17. doi: 10.1002/eji.1830240303. Eur J Immunol. 1994. PMID: 7510232 - Molecular control of B lymphocyte growth and differentiation.
Banchereau J, Brière F, Liu YJ, Rousset F. Banchereau J, et al. Stem Cells. 1994 May;12(3):278-88. doi: 10.1002/stem.5530120304. Stem Cells. 1994. PMID: 7521239 Review. - Molecules controlling B-lymphocyte growth and differentiation.
Banchereau J. Banchereau J. Contrib Nephrol. 1995;111:55-9. doi: 10.1159/000423877. Contrib Nephrol. 1995. PMID: 7538930 Review. No abstract available.
Cited by
- Safety and tolerability of tegoprubart in patients with amyotrophic lateral sclerosis: A Phase 2A clinical trial.
Perrin S, Ladha S, Maragakis N, Rivner MH, Katz J, Genge A, Olney N, Lange D, Heitzman D, Bodkin C, Jawdat O, Goyal NA, Bornstein JD, Mak C, Appel SH, Paganoni S. Perrin S, et al. PLoS Med. 2024 Oct 31;21(10):e1004469. doi: 10.1371/journal.pmed.1004469. eCollection 2024 Oct. PLoS Med. 2024. PMID: 39480764 Free PMC article. Clinical Trial. - Bioinspired Hierarchical Carbon Structures as Potential Scaffolds for Wound Healing and Tissue Regeneration Applications.
Parikh SD, Wang W, Nelson MT, Sulentic CEW, Mukhopadhyay SM. Parikh SD, et al. Nanomaterials (Basel). 2023 Jun 2;13(11):1791. doi: 10.3390/nano13111791. Nanomaterials (Basel). 2023. PMID: 37299693 Free PMC article. - FcγRs and Their Relevance for the Activity of Anti-CD40 Antibodies.
Lang I, Zaitseva O, Wajant H. Lang I, et al. Int J Mol Sci. 2022 Oct 25;23(21):12869. doi: 10.3390/ijms232112869. Int J Mol Sci. 2022. PMID: 36361658 Free PMC article. Review. - Fingolimod-Conjugated Charge-Altering Releasable Transporters Efficiently and Specifically Deliver mRNA to Lymphocytes In Vivo and In Vitro.
Testa S, Haabeth OAW, Blake TR, Del Castillo TJ, Czerwinski DK, Rajapaksa R, Wender PA, Waymouth RM, Levy R. Testa S, et al. Biomacromolecules. 2022 Jul 11;23(7):2976-2988. doi: 10.1021/acs.biomac.2c00469. Epub 2022 Jun 24. Biomacromolecules. 2022. PMID: 35748182 Free PMC article. - The Inhibition of CD40/CD154 Costimulatory Signaling in the Prevention of Renal Transplant Rejection in Nonhuman Primates: A Systematic Review and Meta Analysis.
Perrin S, Magill M. Perrin S, et al. Front Immunol. 2022 Apr 7;13:861471. doi: 10.3389/fimmu.2022.861471. eCollection 2022. Front Immunol. 2022. PMID: 35464470 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials